INDSWFTLAB379.00

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt16.640.617.917.9
Net Debt-415.3-426.8-423.8-423.8
Total Debt/Equity0.020.030.010.01
Net Debt/Equity-0.45-0.36-0.31-0.31
Total Debt/EBITDA0.07-2.090.400.40
Net Debt/EBITDA-1.6322.01-9.40-7.10
Interest Coverage (EBIT/Interest)3.93-15.0310.3110.31
Total Debt/Total Capital %1.753.351.281.28
As Filed — company-reported covenants
Debt Service Coverage (as filed)6.00
Interest Service Coverage (as filed)6.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.